What is the life expectancy of someone with Amyloidosis?

Life expectancy for individuals with amyloidosis varies significantly depending on the specific type of amyloid protein involved, the organs affected, and how early the condition is diagnosed and treated.

Understanding the Variability of Amyloidosis

Because amyloidosis is not a single disease but a group of conditions caused by the buildup of misfolded proteins in tissues and organs, providing a single life expectancy figure is medically inaccurate and misleading. Prognosis depends heavily on whether the disease is systemic or localized, and whether it is AL (light chain) amyloidosis, ATTR (transthyretin) amyloidosis, or another rarer form. Factors such as cardiac involvement, renal function, and the patient’s overall physiological reserve play a critical role in determining individual outcomes.

The Impact of Modern Treatment

We are currently in a transformative era for amyloidosis care. Over the last decade, the clinical landscape has shifted dramatically; new targeted therapies, such as TTR stabilizers and silencers for ATTR amyloidosis, and novel monoclonal antibodies for AL amyloidosis, have significantly improved survival rates and quality of life. Early diagnosis is the most vital factor in these improved outcomes, as preventing organ damage is far more effective than attempting to reverse it once significant deposition has occurred.

Focusing on Quality of Life

While longevity is a common concern, we emphasize that amyloidosis management is increasingly focused on "living well." Our clinical goal is to stabilize organ function, manage symptoms like fatigue or heart failure, and maintain your independence. Regular follow-up with a multidisciplinary team—including cardiologists, hematologists, and nephrologists—is essential to monitor disease progression and adjust treatment protocols in real-time. By staying engaged with your medical team and the amyloidosis community, you gain access to supportive care strategies that prioritize your daily comfort and emotional well-being alongside clinical milestones.

Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: The portal for rare diseases and orphan drugs


• Amyloidosis Foundation